Regeneron (REGN) Tops Q2 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Regeneron (REGN) Tops Q2 EPS by 75c
August 3, 2018 5:10 AM EDT
Barclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $305.00 (from $290.00) while maintaining a Underweight rating.
...
More
August 2, 2018 3:51 PM EDT
Cowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
August 2, 2018 3:27 PM EDT
Oppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Hartaj Singh notes a positive outlook on the shares, as REGN reported second quarter earnings per share and sales... More
August 2, 2018 11:48 AM EDT
Evercore ISI raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $405.00) while maintaining a Outperform rating.
Analyst Josh Schimer noted strong performance across the board for product revenue and expenses. Dupixent/OUS Eylea were strongest spots.
...
More
